Theresa Bunse
Heidelberg, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.
Journal: Nature cancer
Published: August 03, 2026
Primary mismatch repair deficient glioma, IDH-wildtype and H3-wildtype: A giant cell tumor with potential for long-term survival occurring at all ages.
Journal: Neuro-oncology
Published: December 15, 2025
Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.
Journal: Neuro-oncology
Published: December 15, 2025
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.
Journal: Nature cancer
Published: October 30, 2025
Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen.
Journal: Nature communications
Published: July 26, 2024
Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases.
Journal: Cancer research communications
Published: January 11, 2024
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Journal: Neurological research and practice
Published: September 12, 2023
Tumor-reactive T helper cells in the context of vaccination against glioma.
Journal: Cancer cell
Published: May 21, 2023
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells.
Journal: Neuro-oncology advances
Published: October 05, 2022
Clinical and Translational Advances in Glioma Immunotherapy.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: October 03, 2022
Last Updated: 09/26/2026